{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:28:46Z","timestamp":1790252926235,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3278-3","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T08:49:33Z","timestamp":1533286173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir\/Ledipasvir in HCV\/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Cristina Aurora S\u00e3o Pedro","family":"Soeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina Andreia Melo","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Sofia Correia","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Josefina Vazquez","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Ribeiro Almeida","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria Lacerda Morgado Fernandes","family":"Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Manuel do Ros\u00e1rio","family":"Sarmento-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"3278_CR1","unstructured":"World Health Organization. \n                    http:\/\/www.who.int\/hiv\/topics\/hepatitis\n                    \n                  . Accessed July 2017."},{"key":"3278_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","volume":"384","author":"CJ Smith","year":"2014","unstructured":"Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:a:D): a multicohort collaboration. Lancet. 2014;384:241\u20138.","journal-title":"Lancet"},{"key":"3278_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1468-1293.2012.01051.x","volume":"14","author":"R Weber","year":"2013","unstructured":"Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med. 2013;14:195\u2013207.","journal-title":"HIV Med"},{"issue":"6","key":"3278_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M13-1829","volume":"160","author":"LR Re","year":"2014","unstructured":"Re LR, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated HIV\/hepatitis C-Coinfected compared to hepatitis C-Monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369\u20137.9.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3278_CR5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562\u20139.","journal-title":"Clin Infect Dis"},{"key":"3278_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362\u201371.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3278_CR7","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/cit103","volume":"56","author":"JA Mira","year":"2013","unstructured":"Mira JA, Rivero-Ju\u00e1rez A, L\u00f3pez-Cort\u00e9s LF, Gir\u00f3n-Gonz\u00e1lez JA, T\u00e9llez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56:1646\u201353.","journal-title":"Clin Infect Dis"},{"key":"3278_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jhep.2015.06.034","volume":"63","author":"JE Arends","year":"2015","unstructured":"Arends JE, Lieveld FI, Boeijen LL, Kanter CTMM, Erpecum KJ, Salmon D, et al. Natural history and treatment of HCV\/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63:1254\u201362.","journal-title":"J Hepatol"},{"issue":"12","key":"3278_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1097\/QAD.0000000000001135","volume":"30","author":"E Cachay","year":"2016","unstructured":"Cachay E, Soriano V. Is HIV still a special population for the treatment of hepatitis C? AIDS. 2016;30(12):2001\u20133.","journal-title":"AIDS"},{"key":"3278_CR10","unstructured":"Langness J, Larson B, Bayer J, Rogers M, Kiser J. Readying HIV\/HCV coinfected patients for HCV treatment: occurrence and management of antiviral interactions. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 2015, Washington. Abstract 18. \n                    http:\/\/regist2.virology-education.com\/2015\/16HIVHEP\/34_Langness.pdf\n                    \n                  . Accessed Dec 2016."},{"key":"3278_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in patients Coinfected with HIV-1. N Engl J Med. 2015;373:705\u201313.","journal-title":"N Engl J Med"},{"key":"3278_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/liv.13036","volume":"36","author":"AA Butt","year":"2016","unstructured":"Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Intent. 2016;36:651\u20138.","journal-title":"Liver Intent"},{"key":"3278_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/COH.0000000000000185","volume":"10","author":"O El-Sherif","year":"2015","unstructured":"El-Sherif O, Khoo S, Solas C. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS. 2015;10:348\u201354.","journal-title":"Curr Opin HIV AIDS"},{"key":"3278_CR14","unstructured":"German P, Garrison K, Pang PS, Stamm LM, Ray AS, Shen G, et al. Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir\/Sofosbuvir and Antiretrovirals. In: Conference on Retroviruses and Opportunistic Infections. 2015, Seattle. Abstract 82. \n                    http:\/\/www.croiconference.org\/sessions\/drug-drug-interactions-between-anti-hcv-regimen-ledipasvirsofosbuvir-and-antiretrovirals\n                    \n                  . Accessed Dec 2016."},{"key":"3278_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","journal-title":"J Hepatol"},{"key":"3278_CR16","unstructured":"AASLD\/IDSA HCV Guidance Panel. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. \n                    http:\/\/www.hcvguidelines.org\n                    \n                  . Accessed July 2017."},{"key":"3278_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40121-015-0061-2","volume":"4","author":"K Kaur","year":"2015","unstructured":"Kaur K, Gandhi MA, Slish J. Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Infect Dis Ther. 2015;4:159\u201372.","journal-title":"Infect Dis Ther"},{"issue":"12","key":"3278_CR18","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/cid\/cix111","volume":"64","author":"D Bhattacharya","year":"2017","unstructured":"Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus\/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clin Infect Dis. 2017;64(12):1711\u201320.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"3278_CR19","first-page":"30085","volume":"S2210-7401","author":"L Taramasso","year":"2017","unstructured":"Taramasso L, Ricci E, Celesia BM, Bonfanti P, Quirino T, Squillace N, et al. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir\/ledipasvir treatment for HCV infection: much ado about nothing? Clin Res Hepatol Gastroenterol. 2017;S2210-7401(17):30085\u20132.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"3278_CR20","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1002\/phar.1803","volume":"36","author":"KL Bunnell","year":"2016","unstructured":"Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huhn G. Nephrotoxicity associated with concomitant use of Ledipasvir-Sofosbuvir and Tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy. 2016;36(9):e148\u201353.","journal-title":"Pharmacotherapy"},{"key":"3278_CR21","unstructured":"ClinicalTrials.gov. Effects of Sofosbuvir\/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02588287\n                    \n                  . Accessed July 2017."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3278-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T19:05:36Z","timestamp":1564772736000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3278"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3278-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"28 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethical Commission of Centro Hospitalar do Porto and by the Portuguese National Data Protection Commission. Written informed consent was obtained for all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed with the final manuscript and consented publication. Participants consented publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"364"}}